Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)

Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai kit Ming, Yingnan Zhao, Yan Li, Lizheng Shi

Research output: Contribution to journalComment/debate

6 Scopus citations

Abstract

The term “CORE diabetes model” was used throughout the article for consistency. However, there is variation in referencing the original “CORE diabetes model” in the literature [1]: among a total of 37 relevant cost-effectiveness analysis studies published from 2007 to 1 June 2018, 13 studies referenced the model as the “CORE Diabetes Model”, 21 as the “IMS CORE Diabetes Model”, two as the “QuintilesIMS Health CORE Diabetes Model”, and one as the “IQVIA CORE Diabetes Model”. The existence in the literature of multiple names for this model is due to company mergers. For clarification, since 2017 this model has officially been called the “IQVIA CORE Diabetes Model”.

Original languageEnglish
Pages (from-to)1553
Number of pages1
JournalPharmacoEconomics
Volume37
Issue number12
DOIs
StatePublished - 1 Dec 2019

Fingerprint

Dive into the research topics of 'Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review (PharmacoEconomics, (2019), 37, 6, (777-818), 10.1007/s40273-019-00774-9)'. Together they form a unique fingerprint.

Cite this